Invitrogen SNPsteam uses Luminex's platform
Wednesday November 28, 7:03 am Eastern Time
Press Release
SOURCE: Orchid BioSciences, Inc.; Invitrogen Corporation
Orchid and Invitrogen Announce Exclusive Agreement for New SNP Scoring Kits
- Enables Researchers to Perform High Quality Genotyping Without Expensive Equipment -
PRINCETON, N.J. and SAN DIEGO, Nov. 28 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - news) and Invitrogen Corporation (Nasdaq: IVGN - news) today announced that they have entered into an agreement under which Invitrogen acquires exclusive worldwide rights to offer genotyping products to the research market utilizing Orchid's proprietary SNP scoring technology in a 96-well format. Under the terms of the agreement, Invitrogen can develop, manufacture and market genotyping kits using Orchid's proprietary SNP scoring technology and offer customers access to Orchid's proprietary SNP primer design algorithms. Invitrogen will pay Orchid a royalty on kit sales.
``As genomics affects every area of the life sciences, researchers increasingly want to include genetic variability analyses in their studies. Orchid, the leading provider of advanced genotyping products and services for the analysis of SNPs, sought a partner who could help bring the benefits of its sophisticated genotyping technology to the thousands of scientists who want to perform high quality SNP scoring without the need for costly capital equipment,'' said Jack T. Ball, Jr., senior vice president and general manager of Orchid's Life Sciences Group. ``With their worldwide sales and marketing coverage, Invitrogen is an acknowledged leader in providing technically advanced reagent kits to thousands of laboratories. We are delighted to have them as our partner for this important application of our market leading SNP genotyping technology.''
As developed for 96-well format SNP genotyping applications, Orchid's proprietary SNP-IT(TM) primer extension technology provides researchers with the capability to generate hundreds of SNP genotypes per day either visually or by using a standard 96-well plate reader found in virtually every life sciences laboratory.
``Invitrogen has a well-earned reputation among its many thousands of customers for providing new, leading life science technologies in formats that make them accessible to laboratories of all sizes and resource levels,'' said Lyle Turner, chairman and CEO of Invitrogen. ``The agreement with Orchid is consistent with our strategy of in-licensing high potential technologies. Now we can bring the premier technology for accurate, rapid and flexible SNP genotyping to scientists worldwide.''
As part of the agreement, Invitrogen has also obtained rights to provide its customers with access to the SNP primer design algorithms that are currently available through Orchid's AutoPrimer.com web site. This site enables simple and reliable design of primers for use in combination with Orchid's SNP-IT technology. Invitrogen intends to meet customer needs for primers through its custom primer business. Orchid and Invitrogen also have the option to exchange certain intellectual property rights around the design and use of gene specific primer sets. In addition, Invitrogen has agreed to refer customers expressing an interest in the use of Orchid's SNP scoring technology in applications requiring high throughput genotyping systems to Orchid. Further terms of the agreement were not disclosed.
SOURCE: Orchid BioSciences, Inc.; Invitrogen Corporation |
